Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MERTK | Q12866 | 5/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.37 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.37 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 3/20 | 0.36 |
| ▸ | TYRO3 | Q06418 | 3/20 | 0.36 |
| ▸ | GAS6 | Q14393 | 3/20 | 0.36 |
| ▸ | AXL | P30530 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | ITK | Q08881 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15469746 | 0.82 | TLR8 (0.41) | CYP2D6CYP1A2SYKMERTKTLR7 | |
| SCHEMBL13195105 | 0.82 | STK17B (0.42) | SYKMERTKTLR8STK17BSTK17A | |
| SCHEMBL13195672 | 0.81 | CYP2D6 (0.55) | CYP2D6CYP2C9CYP1A2CYP3A4TLR7 | |
| SCHEMBL20219561 | 0.80 | CYP2D6 (0.46) | CYP2D6CYP2C9CYP1A2CYP3A4MERTK | |
| SCHEMBL23472656 | 0.79 | CYP2D6 (0.48) | CYP2D6CYP2C9CYP1A2CYP3A4MERTK | |
| SCHEMBL15469750 | 0.77 | LMNA (0.40) | CYP2D6CYP2C9CYP1A2CYP3A4MERTK | |
| SCHEMBL17123643 | 0.77 | CYP1A2 (0.52) | CYP2D6CYP1A2CYP3A4MERTKTLR7 | |
| SCHEMBL15469749 | 0.76 | MERTK (0.41) | MERTKTLR8STK17BSTK17AFLT3 | |
| SCHEMBL20219443 | 0.76 | MERTK (0.39) | SYKMERTKTLR8STK17BSTK17A | |
| SCHEMBL20386594 | 0.73 | CYP1A2 (0.48) | CYP2D6CYP1A2MERTKTLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-03 | — | — | US | disclosed |
| EP-3590928-B1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2021-06-09 | — | — | EP | disclosed |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2021-01-28 | — | — | US | disclosed |
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2020-09-22 | — | — | US | disclosed |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-27 | — | — | US | disclosed |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-09-24 | — | — | US | disclosed |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-04-30 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| EP-3330257-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland UC (IE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | CYP2D6 361/4885CYP2C9 370/4885CYP1A2 714/4885 |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | CYP2D6 361/4885CYP2C9 370/4885CYP1A2 714/4885 |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | CYP2D6 361/4885CYP2C9 370/4885CYP1A2 714/4885 |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | CYP2D6 361/4885CYP2C9 370/4885CYP1A2 714/4885 |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | CYP2D6 361/4885CYP2C9 370/4885CYP1A2 714/4885 |
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | CYP2D6 361/4885CYP2C9 370/4885CYP1A2 714/4885 |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | CYP2D6 361/4885CYP2C9 370/4885CYP1A2 714/4885 |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | CYP2D6 361/4885CYP2C9 370/4885CYP1A2 714/4885 |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | CYP2D6 361/4885CYP2C9 370/4885CYP1A2 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.